Adjuvant Chemotherapy in NSCLC: State-of-the-Art
Side-effects of CT have been a concern since the first trials, when compliance was suboptimal most of the times. Table 2 shows the most relevant grades III, IV side effects in the above mentioned trials.
Notwithstanding, it must be remarked that toxicity tends to be transient and solved a few months after adjuvant therapy has been finished. This was exemplified by Bezjak with data from trial JBR-10. He showed that with the exception of sensory neuropathy and hearing loss, the rest of side effects were recovered and quality of live returned to the baseline by 9 months after treatment.
Potential damage of pulmonary functional activity has been another fear after AC in these patients. However, a recent paper noted that no decrease in pulmonary function was seen after chemotherapy in 132 patients included in a clinical trial.
Toxicity
Side-effects of CT have been a concern since the first trials, when compliance was suboptimal most of the times. Table 2 shows the most relevant grades III, IV side effects in the above mentioned trials.
Notwithstanding, it must be remarked that toxicity tends to be transient and solved a few months after adjuvant therapy has been finished. This was exemplified by Bezjak with data from trial JBR-10. He showed that with the exception of sensory neuropathy and hearing loss, the rest of side effects were recovered and quality of live returned to the baseline by 9 months after treatment.
Potential damage of pulmonary functional activity has been another fear after AC in these patients. However, a recent paper noted that no decrease in pulmonary function was seen after chemotherapy in 132 patients included in a clinical trial.
SHARE
![Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI]-Special Population](https://cdnus.oss-us-west-1.aliyuncs.com/libs/images/NewsJpg/cate_6/039_215x160.jpg)
